SecBot SecBot

AZR

Azora Therapeutics, Inc. (DE)
Nasdaq· CIK 0001513525 Biotech & Drug Discovery
$3.66 −0.14 (−3.81%)
Nov 17 4:00 PM ET · prev $3.81
Market cap
$58.4M
Micro cap
Median target
$12.00
+227% · range $6.00–14.00
1 year
−52.7%
from $7.75 · Nov 18
30 days
+1.2%
from $3.62
52-week range
$1.36–8.25
−56% from high · low May 14
Avg volume 20D
46.3K
Oct 30 spike 169.2K
Short interest
217.2K
≈8.3% of shares · +20.9%
Days to cover
4.1
at average volume
Insider net
+$206.3K
2 buyers · 0 sellers · 12 mo
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 2 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $206.3K at an average $2.70. No open-market sales. Price is 36% above their cost.

  • Short sellersBUILDING

    Short interest +20.9% to 217.2K shares. 4.1 days to cover, ≈8.3% of shares.

  • TrendRANGE

    12% below its 50-day average.

Insider ledger

Form 4
$206.3K
bought · 2 insiders
$0
sold · 0 insiders
+35.6%
vs their $2.70 cost
DateInsiderTypeValue
Nov 2, 2026
Saiki Julie
Chief Strategy Officer
Nov 2, 2026
CONVERT626,252 sh
Nov 2, 2026
Davidson Matt
President and CEO
Nov 2, 2026
CONVERT101.298 sh
Nov 2, 2026
Davidson Matt
President and CEO
Nov 2, 2026
CONVERT101,298 sh
Nov 2, 2026
Saiki Julie
Chief Strategy Officer
Nov 2, 2026
CONVERT626.252 sh
Nov 2, 2026
Davidson Matt
President and CEO
Nov 2, 2026
CONVERT524.954 sh
Nov 2, 2026
Davidson Matt
President and CEO
Nov 2, 2026
CONVERT524,954 sh
Oct 28, 2026
Davidson Matt
President and CEO
Oct 28, 2026
AWARD232,417 sh
Oct 28, 2026
Davidson Matt
President and CEO
Oct 28, 2026
AWARD333,830 sh

Earnings setup

Estimates
−$0.13
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.13–-$0.13No data$0.00
Next Q-$0.21-$0.21–-$0.21No data$0.00
Current FY-$4.94-$4.94–-$4.94No data$0.00
Next FY-$0.49-$0.49–-$0.49No data$0.00

Short side

FINRA· Oct 30, 2026
217,174
shares short
+20.9%
vs prior settlement
4.1
days to cover
≈8.3%
of shares outstanding
Trading halts
Nov 2, 2026Volatility PauseResumed
Nov 2, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Azora Therapeutics (formerly Adial Pharmaceuticals) reported Q3 2026 results post-merger: net loss of $64.6M ($4.52…
8-K · Impact 4/10
Nov 12, 2026 Earnings
Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
Azora Therapeutics commenced trading on Nasdaq as “AZR”
Nov 10, 2026 SEC
Three new insiders, Paul J. Hastings, Aida Habtezion, and Thomas M. Soloway, filed initial statements of beneficial…
3 · Impact 2/10
Nov 2, 2026 Insider
Saiki Julie acquired 626,252 shares
Chief Strategy Officer
Nov 2, 2026 Insider
Davidson Matt disposed of 101.298 shares
President and CEO
Nov 2, 2026 Insider
Davidson Matt acquired 101,298 shares
President and CEO

SecBot reports

5 filings · 0 bullish · 2 bearish · 3 neutral
All AZR filing & press-release reports (5)